Effect of hyperfiltration on long-term follow-up of glomerular filtration rate in male Wistar rats

1994 ◽  
Vol 8 (6) ◽  
pp. 710-714 ◽  
Author(s):  
A. Piepsz ◽  
F. Collier ◽  
J. Kinthaert ◽  
K. Vanden Haute ◽  
M. Hall ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Wistar Rats ◽  
Filtration Rate ◽  
Long Term Follow Up ◽  
Male Wistar Rats

scholarly journals Long-term follow-up of blood pressure and glomerular filtration rate in patients with a solitary functioning kidney: a comparison between Wilms tumor survivors and nephrectomy for other reasons

2015 ◽  
Vol 31 (3) ◽  
pp. 435-441 ◽  
Author(s):  
Annelies M. C. Mavinkurve-Groothuis ◽  
Frank van de Kracht ◽  
Rik Westland ◽  
Joanna A. E. van Wijk ◽  
Jacqueline J. Loonen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Filtration Rate ◽  
Wilms Tumor ◽  
Solitary Functioning Kidney ◽  
Long Term Follow Up ◽  
Functioning Kidney

Long-Term Follow-Up of Separate Glomerular Filtration Rate in Partially Obstructed Kidneys

1988 ◽  
Vol 22 (4) ◽  
pp. 327-333 ◽  
Author(s):  
A. Piepsz ◽  
H. R. Ham ◽  
M. Hall ◽  
Y. Thoua ◽  
J. L. Froideville ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Filtration Rate ◽  
Long Term Follow Up

scholarly journals Relationship between Estimated Glomerular Filtration Rate and Cardiovascular Mortality in a Japanese Cohort with Long-Term Follow-Up

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0156792 ◽  
Author(s):  
Kei Nagai ◽  
Toshimi Sairenchi ◽  
Fujiko Irie ◽  
Hiroshi Watanabe ◽  
Hitoshi Ota ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Cardiovascular Mortality ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Japanese Cohort ◽  
Long Term Follow Up

scholarly journals Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142491 ◽  
Author(s):  
Hélène Peyriere ◽  
Amandine Cournil ◽  
Marie-Laure Casanova ◽  
Stéphanie Badiou ◽  
Jean-Paul Cristol ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Tubular Proteinuria ◽  
Long Term Follow Up

P0230IMMUNOSUPPRESSIVE TREATMENT DOES NOT IMPROVE KIDNEY SURVIVAL IN PATIENTS WITH HCV CRYOGLOBULINAEMIA TREATED WITH DIRECT-ACTING ANTIVIRALS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Pérez de José Ana ◽  
Javier Carbayo ◽  
Anna Pocurull ◽  
Ana Huerta ◽  
Clara Maria Cases Corona ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Viral Load ◽  
Glomerular Filtration ◽  
Filtration Rate ◽  
Immunosuppressive Treatment ◽  
Immunological Response ◽  
Direct Acting Antivirals ◽  
Direct Acting

Abstract Background and Aims Since the introduction of direct-acting antivirals (DAAs), few data have been published about kidney outcome in hepatitis C virus related mixed cryoglobulinaemia (HCV-MC) patients treated with combined DAAs and rituximab. We aimed to asses if combined treatment with DAAs and rituximab in patients with HCV-MC improves kidney survival and immunological response. Method Observational, multicentre, cohort study of 100 patients with HCV-MC from 14 Spanish centres treated with DAAs. Patients were followed up for a median duration of 138 months (11.5 years). Long-term kidney survival and immunological response were evaluated based on immunosuppressive treatment received. Kidney event was defined as duplication of creatinine level or 50% decrease in glomerular filtration rate, dependence on renal replacement therapy or non-reduction of proteinuria by 50% compared to baseline. Immunological response was defined as the decrease in cryocrit ≤1%. Results Sustained virological response was attained in 98 (98%) patients. 49 patients were treated with immunosuppressive treatment associated with DAAs, 26 with rituximab and the rest (23) with steroids and/or cyclophosphamide. Patients receiving immunosuppressive treatment had higher basal cryocrit (6.3±4.5 vs 3.8±3.9%, p=0.011), lower glomerular filtration rate (55±27 vs 68±25 ml/min/1.73 m2) and more haematuria (p=0.001). The 26 patients treated with rituximab had more severe disease: higher viral load (p=0.001), cryocrit (p=0.011), proteinuria (p=0.004), microhaematuria (p=0.012) and hypertension (p=0.012) and lower glomerular filtration rate (p=0.001). 15 patients had a kidney event at the end of follow-up. Predictive variables of kidney events were lower age (HR 0.94, 95%CI 0.89-0.99; P= 0.038) and lower glomerular filtrate rate (HR 0.97, 95%CI 0.94-0.99; p=0.026), in a model adjusted to proteinuria and microhaematuria. Immunosuppressive treatment with or without rituximab did not change kidney survival. Regarding the immunological response, only 19 patients had a cryocrit >1% at the end of follow-up. There were no differences in age, viral load, proteinuria and basal glomerular filtration rate between these patients with no immunological response and those who had a sustained immunological response over time. The only differences between these two groups were a higher basal cryocrit and a minor C4 levels. Immunosuppressive treatment with or without rituximab did not changed the immunological response. Conclusion Patients with more severe HCV-MC are those receiving immunosuppressive treatment. However, immunosuppressive treatment does not change kidney survival nor immunological response of these patients in the long term.

Sign in / Sign up

Export Citation Format

Share Document